Callie Coombs, MD, of the University of California, Irvine, discusses what she is most looking forward to in chronic lymphocytic leukemia (CLL) at the Society of Hematologic Oncology 2024 Annual Meeting.
Specifically, Dr. Coombs discussed time limited therapies and the phase III AMPLIFY trial, which evaluated acalabrutinib plus venetoclax in patients with CLL.